Discovering significant breakthroughs in fibrosis.
Blade Clinical Trials
We are advancing a robust pipeline of potential first and best-in-class investigational small-molecule therapies to combat diseases of lung (acute and chronic), liver and heart fibrosis, as well as neuro-degenerative conditions. This includes multiple direct inhibitors of autotaxin / LPA and dimeric calpains that offer distinct but complementary anti-fibrotic mechanisms.
Find Clinical Trials Near Me
| Program | Indication | Study Phase | Status | Trial number |
|---|---|---|---|---|
| BLD-0409 | Healthy Volunteer Safety Testing | Phase 1 | Active | NCT04146805 |
| BLD-0409-107 | Liver Impairment Study | Phase 1b | Planned | |
| BLD-0409-210 | Interstitial Lung Disease | Phase 2 | Planned |
Chronic Liver Disease
Blade’s autotaxin inhibitor, BLD-0409, is being studied in a Phase 1 double-blind, randomized, placebo-controlled, multiple cohort, single and multiple ascending dose trial to assess safety, tolerability and pharmacokinetics in healthy participants (Clinicaltrials.gov NCT04146805).